Drug Profile
Research programme: small molecule MAPKAPK2 inhibitors - MetaStat
Alternative Names: small molecules targeting Mena protein isoformLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator MetaStat Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer